Royal Bank of Canada’s Crinetics Pharmaceuticals CRNX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.91M | Buy |
50,880
+1,102
| +2% | +$41K | ﹤0.01% | 3361 |
|
|
2026
Q1 | $1.81M | Buy |
49,778
+2,483
| +5% | +$111K | ﹤0.01% | 3168 |
|
|
2025
Q4 | $2.2M | Sell |
47,295
-123,200
| -72% | -$5.48M | ﹤0.01% | 3068 |
|
|
2025
Q3 | $7.1M | Sell |
170,495
-1,984
| -1% | -$63.4K | ﹤0.01% | 2402 |
|
|
2025
Q2 | $4.96M | Buy |
172,479
+145,743
| +545% | +$4.5M | ﹤0.01% | 2573 |
|
|
2025
Q1 | $897K | Sell |
26,736
-2,544
| -9% | -$95K | ﹤0.01% | 3562 |
|
|
2024
Q4 | $1.5M | Sell |
29,280
-5,803
| -17% | -$325K | ﹤0.01% | 3232 |
|
|
2024
Q3 | $1.79M | Buy |
35,083
+3,417
| +11% | +$176K | ﹤0.01% | 3073 |
|
|
2024
Q2 | $1.42M | Buy |
31,666
+6,641
| +27% | +$307K | ﹤0.01% | 3169 |
|
|
2024
Q1 | $1.17M | Buy |
25,025
+4,010
| +19% | +$157K | ﹤0.01% | 3329 |
|
|
2023
Q4 | $749K | Buy |
21,015
+10,211
| +95% | +$313K | ﹤0.01% | 3898 |
|
|
2023
Q3 | $321K | Buy |
10,804
+5,209
| +93% | +$107K | ﹤0.01% | 4390 |
|
|
2023
Q2 | $100K | Buy |
5,595
+2,201
| +65% | +$43.9K | ﹤0.01% | 5337 |
|
|
2023
Q1 | $54K | Sell |
3,394
-3,496
| -51% | -$64.7K | ﹤0.01% | 5577 |
|
|
2022
Q4 | $126K | Buy |
6,890
+5,883
| +584% | +$104K | ﹤0.01% | 5278 |
|
|
2022
Q3 | $20K | Buy |
1,007
+345
| +52% | +$7.04K | ﹤0.01% | 6133 |
|
|
2022
Q2 | $13K | Sell |
662
-2,426
| -79% | -$48.4K | ﹤0.01% | 6267 |
|
|
2022
Q1 | $68K | Sell |
3,088
-6,735
| -69% | -$136K | ﹤0.01% | 5883 |
|
|
2021
Q4 | $279K | Buy |
9,823
+6,546
| +200% | +$161K | ﹤0.01% | 5010 |
|
|
2021
Q3 | $69K | Buy |
3,277
+380
| +13% | +$7.95K | ﹤0.01% | 5963 |
|
|
2021
Q2 | $55K | Buy |
2,897
+1,111
| +62% | +$19.5K | ﹤0.01% | 5969 |
|
|
2021
Q1 | $27K | Buy |
1,786
+1,219
| +215% | +$18.9K | ﹤0.01% | 6246 |
|
|
2020
Q4 | $8K | Buy |
567
+530
| +1,432% | +$7.38K | ﹤0.01% | 6469 |
|
|
2020
Q3 | $1K | Sell |
37
-686
| -95% | -$10.5K | ﹤0.01% | 6404 |
|
|
2020
Q2 | $12K | Buy |
723
+447
| +162% | +$7.62K | ﹤0.01% | 5765 |
|
|
2020
Q1 | $4K | Sell |
276
-206
| -43% | -$4.22K | ﹤0.01% | 6103 |
|
|
2019
Q4 | $12K | Buy |
482
+67
| +16% | +$1.28K | ﹤0.01% | 6068 |
|
|
2019
Q3 | $6K | Hold |
415
| – | – | ﹤0.01% | 5942 |
|
|
2019
Q2 | $10K | Hold |
415
| – | – | ﹤0.01% | 6019 |
|
|
2019
Q1 | $9K | Buy |
415
+385
| +1,283% | +$9.46K | ﹤0.01% | 6029 |
|
|
2018
Q4 | $1K | Sell |
30
-298
| -91% | -$8.39K | ﹤0.01% | 6554 |
|
|
2018
Q3 | $9K | Buy |
+328
| New | +$9.74K | ﹤0.01% | 6022 |
|
Other funds holding CRNX
FCM
DCM
JT
Royal Bank of Canada's CRNX Position: Q2 2026 in Review
Royal Bank of Canada increased its Crinetics Pharmaceuticals (CRNX) stake by 2.2% in Q2 2026, buying an estimated $41K and bringing the position to 50,880 shares worth $1.91M. The position accounts for ﹤0.01% of the portfolio, ranked #3361.
Royal Bank of Canada first reported a position in CRNX in Q3 2018 and has held it in 32 quarters since. The position peaked at $7.1M in Q3 2025. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.
- Royal Bank of Canada held 50,880 shares of Crinetics Pharmaceuticals worth $1.91M as of Q2 2026.
- Royal Bank of Canada bought 1,102 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $41K.
- Crinetics Pharmaceuticals made up ﹤0.01% of Royal Bank of Canada's portfolio in Q2 2026, its #3361 holding.
- Royal Bank of Canada first reported a position in Crinetics Pharmaceuticals in Q3 2018 and has held it in 32 quarters since.
- Royal Bank of Canada's Crinetics Pharmaceuticals position peaked at $7.1M in Q3 2025.
- 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.
Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.